2,975
Views
34
CrossRef citations to date
0
Altmetric
Report

Generation and preclinical characterization of an antibody specific for SEMA4D

, , , , , , , , , , , , , , , , , , & show all
Pages 150-162 | Received 06 Jul 2015, Accepted 25 Sep 2015, Published online: 11 Nov 2015

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (4)

Ernest S. Smith, Leslie A. Balch, Maria Scrivens, Shuying Shi, Wei Wang, Caroline D. Harvey, Angelica A. Cornelison, Malgorzata Gil-Moore, Renee A. Kirk, Loretta L. Mueller, Richard L. Hall, Alan P. Howell, Christine A. Reilly, Jessica M. Mayer, Francis G. Murante, Kari A Viggiani, Elaine M. Gersz, Holm Bussler, Madeleine R. Keefe, Elizabeth E. Evans, Mark J. Paris & Maurice Zauderer. (2023) Use of poxvirus display to select antibodies specific for complex membrane antigens. mAbs 15:1.
Read now
Bruno P. Imbimbo, Madia Lozupone, Mark Watling & Francesco Panza. (2020) Discontinued disease-modifying therapies for Alzheimer’s disease: status and future perspectives. Expert Opinion on Investigational Drugs 29:9, pages 919-933.
Read now
Thomas Müller. (2017) Investigational agents for the management of Huntington’s disease. Expert Opinion on Investigational Drugs 26:2, pages 175-185.
Read now
Sreeharsha Gurrapu & Luca Tamagnone. (2016) Transmembrane semaphorins: Multimodal signaling cues in development and cancer. Cell Adhesion & Migration 10:6, pages 675-691.
Read now

Articles from other publishers (30)

Carmela Matrone & Gabriella Ferretti. (2023) Semaphorin 3A influences neuronal processes that are altered in patients with autism spectrum disorder: Potential diagnostic and therapeutic implications. Neuroscience & Biobehavioral Reviews 153, pages 105338.
Crossref
Daniela Melchiorri, Sara Merlo, Benjamin Micallef, John-Joseph Borg & František Dráfi. (2023) Alzheimer’s disease and neuroinflammation: will new drugs in clinical trials pave the way to a multi-target therapy?. Frontiers in Pharmacology 14.
Crossref
Mariza Fevereiro-Martins, Carlos Marques-Neves, Hercília Guimarães & Manuel Bicho. (2023) Retinopathy of prematurity: A review of pathophysiology and signaling pathways. Survey of Ophthalmology 68:2, pages 175-210.
Crossref
Lu Liu, Lin Yang, Xiaojun Liu, Menghan Liu, Jing Liu, Xuefeng Feng, Ziyuan Nie & Jianmin Luo. (2022) SEMA4D/PlexinB1 promotes AML progression via activation of PI3K/Akt signaling. Journal of Translational Medicine 20:1.
Crossref
Andrew Feigin, Elizabeth E. Evans, Terrence L. Fisher, John E. Leonard, Ernest S. Smith, Alisha Reader, Vikas Mishra, Richard Manber, Kimberly A. Walters, Lisa Kowarski, David Oakes, Eric Siemers, Karl D. Kieburtz, Maurice Zauderer, Elise Kayson, Jody Goldstein, Richard Barbano, Karen Marder, Praveen Dayalu, Herminia Diana Rosas, Sandra Kostyk, John Kamholz, Brad Racette, Jee Bang, Daniel Claassen, Katherine McDonell, Stewart Factor, Francis Walker, Clarisse Goas, Joanne Wojcieszek, Lynn A. Raymond, Jody Corey-Bloom, Victor Sung, Marissa Dean, Michael Geshwind, Alexandra Nelson, Samuel Frank, Kathrin LaFaver, Andrew Duker, Lawrence Elmer, Ali Samii, Yi-Han Lin, Sylvain Chouinard, Lauren Seeberger, Burton Scott, James Boyd, Nikolaus McFarland, Erin Furr Stimming, Oksana Suchowersky, Claudia Testa & Karen Anderson. (2022) Pepinemab antibody blockade of SEMA4D in early Huntington’s disease: a randomized, placebo-controlled, phase 2 trial. Nature Medicine 28:10, pages 2183-2193.
Crossref
Nozomi Sugano-Nakamura, Kyoko Matoba, Mika Hirose, Nasir K. Bashiruddin, Yukiko Matsunaga, Keitaro Yamashita, Kunio Hirata, Masaki Yamamoto, Takao Arimori, Hiroaki Suga & Junichi Takagi. (2022) De novo Fc-based receptor dimerizers differentially modulate PlexinB1 function. Structure 30:10, pages 1411-1423.e4.
Crossref
Elizabeth E. Evans, Vikas Mishra, Crystal Mallow, Elaine M. Gersz, Leslie Balch, Alan Howell, Christine Reilly, Ernest S. Smith, Terrence L. Fisher & Maurice Zauderer. (2022) Semaphorin 4D is upregulated in neurons of diseased brains and triggers astrocyte reactivity. Journal of Neuroinflammation 19:1.
Crossref
Marta Daniela Costa & Patrícia Maciel. (2022) Modifier pathways in polyglutamine (PolyQ) diseases: from genetic screens to drug targets. Cellular and Molecular Life Sciences 79:5.
Crossref
Linda Giampietri, Elisabetta Belli, Maria Francesca Beatino, Sara Giannoni, Giovanni Palermo, Nicole Campese, Gloria Tognoni, Gabriele Siciliano, Roberto Ceravolo, Ciro De Luca & Filippo Baldacci. (2022) Fluid Biomarkers in Alzheimer’s Disease and Other Neurodegenerative Disorders: Toward Integrative Diagnostic Frameworks and Tailored Treatments. Diagnostics 12:4, pages 796.
Crossref
Elisabetta Valentini, Marta Di Martile, Donatella Del Bufalo & Simona D’Aguanno. (2021) SEMAPHORINS and their receptors: focus on the crosstalk between melanoma and hypoxia. Journal of Experimental & Clinical Cancer Research 40:1.
Crossref
Yilin Mao, Elizabeth Evans, Vikas Mishra, Leslie Balch, Allison Eberhardt, Maurice Zauderer & Wendy Gold. (2021) Anti-Semaphorin 4D Rescues Motor, Cognitive, and Respiratory Phenotypes in a Rett Syndrome Mouse Model. International Journal of Molecular Sciences 22:17, pages 9465.
Crossref
Michael R. Shafique, Terrence L. Fisher, Elizabeth E. Evans, John E. Leonard, Desa Rae E. Pastore, Crystal L. Mallow, Ernest Smith, Vikas Mishra, Andreas Schröder, Kevin M. Chin, Joseph T. Beck, Megan A. Baumgart, Ramaswamy Govindan, Nashat Y. Gabrail, Alexander I. Spira, Nagashree Seetharamu, Yanyan Lou, Aaron S. Mansfield, Rachel E. Sanborn, Jonathan W. Goldman & Maurice Zauderer. (2021) A Phase Ib/II Study of Pepinemab in Combination with Avelumab in Advanced Non–Small Cell Lung Cancer. Clinical Cancer Research 27:13, pages 3630-3640.
Crossref
Fabien Binamé, Lucas D. Pham-Van & Dominique Bagnard. (2021) Manipulating oligodendrocyte intrinsic regeneration mechanism to promote remyelination. Cellular and Molecular Life Sciences 78:13, pages 5257-5273.
Crossref
Liu Wang, Xiangfen Li, Yao Song, Dongzhe Song & Dingming Huang. (2020) The emerging roles of semaphorin4D/CD100 in immunological diseases. Biochemical Society Transactions 48:6, pages 2875-2890.
Crossref
Chunying Xiao, Yang Luo, Chen Zhang, Zhenlai Zhu, Luting Yang, Hongjiang Qiao, Meng Fu, Gang Wang, Xu Yao & Wei Li. (2020) Negative regulation of dendritic cell activation in psoriasis mediated via CD100–plexin‐B2. The Journal of Pathology 250:4, pages 409-419.
Crossref
Jie‐hong Wu, Ya‐nan Li, An‐qi Chen, Can‐dong Hong, Chun‐lin Zhang, Hai‐ling Wang, Yi‐fan Zhou, Peng‐Cheng Li, Yong Wang, Ling Mao, Yuan‐peng Xia, Quan‐wei He, Hui‐juan Jin, Zhen‐yu Yue & Bo Hu. (2020) Inhibition of Sema4D/PlexinB1 signaling alleviates vascular dysfunction in diabetic retinopathy. EMBO Molecular Medicine 12:2.
Crossref
Brian M. Kopec, Paul Kiptoo, Liqin Zhao, Eduardo Rosa-Molinar & Teruna J. Siahaan. (2019) Noninvasive Brain Delivery and Efficacy of BDNF to Stimulate Neuroregeneration and Suppression of Disease Relapse in EAE Mice. Molecular Pharmaceutics.
Crossref
Kavisha R. Ulapane, Brian M. Kopec & Teruna J. Siahaan. (2019) In Vivo Brain Delivery and Brain Deposition of Proteins with Various Sizes . Molecular Pharmaceutics 16:12, pages 4878-4889.
Crossref
Luca Tamagnone & Giulia Franzolin. (2019) Targeting Semaphorin 4D in Cancer: A Look from Different Perspectives. Cancer Research 79:20, pages 5146-5148.
Crossref
Iratxe Zuazo-Gaztelu, Marta Pàez-Ribes, Patricia Carrasco, Laura Martín, Adriana Soler, Mar Martínez-Lozano, Roser Pons, Judith Llena, Luis Palomero, Mariona Graupera & Oriol Casanovas. (2019) Antitumor Effects of Anti-Semaphorin 4D Antibody Unravel a Novel Proinvasive Mechanism of Vascular-Targeting Agents. Cancer Research 79:20, pages 5328-5341.
Crossref
Chen Zhang, Hongjiang Qiao, Weinan Guo, Yuan Liu, Luting Yang, Yufeng Liu, Boquan Jin, Meng Fu, Gang Wang & Wei Li. (2019) CD100-plexin-B1 induces epithelial-mesenchymal transition of head and neck squamous cell carcinoma and promotes metastasis. Cancer Letters 455, pages 1-13.
Crossref
Jian-jun Lu, Yao-wu Su, Chao-jun Wang, Di-feng Li & Liang Zhou. (2019) Semaphorin 4D promotes the proliferation and metastasis of bladder cancer by activating the PI3K/AKT pathway. Tumori Journal 105:3, pages 231-242.
Crossref
Anna Laber, Elisabeth Gadermaier, Jacqueline Wallwitz, Gabriela Berg & Gottfried Himmler. (2019) A high-sensitivity enzyme immunoassay for the quantification of soluble human semaphorin 4D in plasma. Analytical Biochemistry 574, pages 15-22.
Crossref
Sebastian Quintremil, Fernando Medina Ferrer, Javier Puente, María Elsa Pando & María Antonieta Valenzuela. 2019. Neurons - Dendrites and Axons. Neurons - Dendrites and Axons.
Maria C. A. Luque, Mariana K. Galuppo, Janaina Capelli-Peixoto & Beatriz S. Stolf. (2018) CD100 Effects in Macrophages and Its Roles in Atherosclerosis. Frontiers in Cardiovascular Medicine 5.
Crossref
Konstantinos Lontos, Juraj Adamik, Anastasia Tsagianni, Deborah L. Galson, John M. Chirgwin & Attaya Suvannasankha. (2018) The Role of Semaphorin 4D in Bone Remodeling and Cancer Metastasis. Frontiers in Endocrinology 9.
Crossref
Christopher LaGankeLawrence SamkoffKeith EdwardsLily Jung HensonPavle RepovicSharon LynchLael StoneDavid MattsonAaron GalluzziTerrence L. FisherChristine ReillyLaurie A. WinterJohn E. LeonardMaurice Zauderer. (2017) Safety/tolerability of the anti-semaphorin 4D antibody VX15/2503 in a randomized phase 1 trial. Neurology Neuroimmunology & Neuroinflammation 4:4.
Crossref
Xiaojun Jiang, Niklas K. Björkström & Espen Melum. (2017) Intact CD100–CD72 Interaction Necessary for TCR-Induced T Cell Proliferation. Frontiers in Immunology 8.
Crossref
Yukiko Matsunaga, Nasir K. Bashiruddin, Yu Kitago, Junichi Takagi & Hiroaki Suga. (2016) Allosteric Inhibition of a Semaphorin 4D Receptor Plexin B1 by a High-Affinity Macrocyclic Peptide. Cell Chemical Biology 23:11, pages 1341-1350.
Crossref
John E. Leonard, Terrence L. Fisher, Laurie A. Winter, Chad A. Cornelius, Christine Reilly, Ernest S. Smith & Maurice Zauderer. (2015) Nonclinical Safety Evaluation of VX15/2503, a Humanized IgG4 Anti-SEMA4D Antibody. Molecular Cancer Therapeutics 14:4, pages 964-972.
Crossref